Neuberger Berman Group
CYTK icon

Neuberger Berman Group’s Cytokinetics CYTK Stock Holding History

Neuberger Berman Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.91M Sell
69,351
-7,742
-10% -$556K ﹤0.01% 1015
2026
Q1 		$5.08M Buy
77,093
+5,715
+8% +$363K ﹤0.01% 977
2025
Q4 		$4.54M Buy
71,378
+65,069
+1,031% +$4.05M ﹤0.01% 992
2025
Q3 		$347K Buy
6,309
+132
+2% +$5.44K ﹤0.01% 1710
2025
Q2 		$204K Sell
6,177
-513
-8% -$17.8K ﹤0.01% 1884
2025
Q1 		$269K Buy
+6,690
New +$307K ﹤0.01% 1736
2024
Q4 		– Sell
-3,874
Closed -$205K – 1950
2024
Q3 		$205K Sell
3,874
-91,492
-96% -$5.1M ﹤0.01% 1789
2024
Q2 		$5.17M Buy
95,366
+17,364
+22% +$1.05M ﹤0.01% 902
2024
Q1 		$5.47M Sell
78,002
-44,444
-36% -$3.44M ﹤0.01% 900
2023
Q4 		$10.2M Buy
122,446
+74,952
+158% +$2.71M ﹤0.01% 908
2023
Q3 		$1.4M Buy
47,494
+2,108
+5% +$70.2K ﹤0.01% 1164
2023
Q2 		$1.48M Buy
45,386
+22,227
+96% +$822K ﹤0.01% 1149
2023
Q1 		$815K Buy
+23,159
New +$945K ﹤0.01% 1316

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's CYTK Position: Q2 2026 in Review

Neuberger Berman Group reduced its Cytokinetics (CYTK) stake by 10% in Q2 2026, selling an estimated $556K and leaving 69,351 shares worth $5.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

Neuberger Berman Group first reported a position in CYTK in Q1 2023 and has held it in 13 quarters since. The position peaked at $10.2M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Neuberger Berman Group held 69,351 shares of Cytokinetics worth $5.91M as of Q2 2026.
  • Neuberger Berman Group sold 7,742 Cytokinetics shares in Q2 2026, an estimated $556K.
  • Cytokinetics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1015 holding.
  • Neuberger Berman Group first reported a position in Cytokinetics in Q1 2023 and has held it in 13 quarters since.
  • Neuberger Berman Group's Cytokinetics position peaked at $10.2M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.